Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation play
Motilal Oswal has reiterated a “buy” rating on Glenmark Pharmaceuticals with a raised target price of Rs 2,430, implying a ...
Motilal Oswal has reiterated a “buy” rating on Glenmark Pharmaceuticals with a raised target price of Rs 2,430, implying a ...
